Research peptide
Selank
Selank is a research peptide indexed in the PeptiBrief evidence database. It has a defined amino-acid sequence in this dossier.
- Sequence
- TKPRPGP
Evidence confidence
Human
3/5
Multiple human studies
2 citations
Animal
2/5
Some animal evidence
1 citation
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
3/5
Reasonable safety characterisation
2 citations
Claimed uses
- Limited human
- Anecdotal
- Insufficient
- Insufficient
Mechanisms
- Modulation of GABA / serotonin signalling
- Immunomodulation
- Enkephalin and GABA-related anxiety signalling
- Neuroplasticity
Safety notes
Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.
Regulation
- Regulatory and marketing status vary by jurisdiction. It is not generally licensed as a medicine in the United States or United Kingdom.
- Not approved for general wellness or performance use unless a specific regulated product and indication exists.
References
- Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats · 2019
- The molecular aspects of heptapeptide Selank biological activity · 2018
- A comparison of the anxiolytic effect and tolerability of Selank and phenazepam · 2014
- Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia · 2008
Last reviewed
12 July 2026